National Bank of Canada
XRTX

National Bank of Canada’s XORTX Therapeutics XRTX Stock Holding History

National Bank of Canada’s Portfolio XRTX Stock Details XRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-787
Closed -$3.9K – 3257
2025
Q2 		$3.9K Buy
787
+752
+2,149% +$3.55K ﹤0.01% 2539
2025
Q1 		$150 Sell
35
-288
-89% -$1.43K ﹤0.01% 2701
2024
Q4 		$1.74K Sell
323
-365
-53% -$2.52K ﹤0.01% 2599
2024
Q3 		$5.64K Buy
+688
New +$5.89K ﹤0.01% 2183

Other funds holding XRTX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

National Bank of Canada's XRTX Position: Q3 2025 in Review

National Bank of Canada sold out of XORTX Therapeutics (XRTX) in Q3 2025, closing a stake of 787 shares — an estimated $3.9K sold.

National Bank of Canada first reported a position in XRTX in Q3 2024 and held it in 4 quarters. The position peaked at $5.64K in Q3 2024. 5 funds tracked by Wall St. Rank hold XRTX as of Q3 2025.

  • National Bank of Canada reported no remaining XORTX Therapeutics position as of Q3 2025 after selling out during the quarter.
  • National Bank of Canada sold 787 XORTX Therapeutics shares in Q3 2025, an estimated $3.9K.
  • National Bank of Canada first reported a position in XORTX Therapeutics in Q3 2024 and held it in 4 quarters.
  • National Bank of Canada's XORTX Therapeutics position peaked at $5.64K in Q3 2024.
  • 5 funds tracked by Wall St. Rank held XORTX Therapeutics as of Q3 2025.

Based on National Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.